Advicenne's Stock Soars Over 55% in a Week Following Approval of Likozam
The Paris-based pharmaceutical company continues its rally in the session, extending a bullish movement that began last week. The stock is challenging a closely watched technical threshold, following the announcement of the reimbursement of its flagship product Likozam by Social Security.
Intra-session Breakthrough of the €1.35 Resistance Following the Reimbursement Announcement
Advicenne's stock is up 7.38% at €1.338 during the session, after reaching a high of €1.38. The stock briefly crossed its €1.35 resistance before slightly falling below it. The weekly gain now exceeds 55%. This movement comes the day after the announcement of the reimbursement of Likozam (clobazam) by the French Social Security starting June 12, 2026. According to the press release published on Monday, the decision concludes the early access phase and creates a €6 million claim on the state, simplifying the financial structure of the specialty pharmaceutical group.
A Vigorous Technical Rebound but the Stock Remains Far from Its Long-Term Average
The rise propels the price well above its short-term averages, with a gap of nearly 44% compared to the MM20 (€0.93) and 7% above the MM50 (€1.25). The RSI at 62 reflects the strength of the rebound without entering the overbought zone, while the MACD histogram moves back into positive territory (0.04), indicating a bullish crossover of the MACD on its signal line. However, the outlook remains mixed in the longer term: the stock is still trading 15% below its MM200 (€1.58) and is down 26% over the year. Over three months, the decline reaches 35.71%, which the recent rally mitigates but does not erase. The sustainable crossing of the €1.35 resistance remains the next technical marker to watch on the stock.
